These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 28486107)

  • 1. RasGRP3 Mediates MAPK Pathway Activation in GNAQ Mutant Uveal Melanoma.
    Chen X; Wu Q; Depeille P; Chen P; Thornton S; Kalirai H; Coupland SE; Roose JP; Bastian BC
    Cancer Cell; 2017 May; 31(5):685-696.e6. PubMed ID: 28486107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.
    Chen X; Wu Q; Tan L; Porter D; Jager MJ; Emery C; Bastian BC
    Oncogene; 2014 Sep; 33(39):4724-34. PubMed ID: 24141786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma.
    Wu X; Zhu M; Fletcher JA; Giobbie-Hurder A; Hodi FS
    PLoS One; 2012; 7(1):e29622. PubMed ID: 22253748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways.
    Wu X; Li J; Zhu M; Fletcher JA; Hodi FS
    Mol Cancer Ther; 2012 Sep; 11(9):1905-14. PubMed ID: 22653968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterogeneity in Mitogen-Activated Protein Kinase (MAPK) Pathway Activation in Uveal Melanoma With Somatic GNAQ and GNA11 Mutations.
    Boru G; Cebulla CM; Sample KM; Massengill JB; Davidorf FH; Abdel-Rahman MH
    Invest Ophthalmol Vis Sci; 2019 Jun; 60(7):2474-2480. PubMed ID: 31173078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner.
    Khalili JS; Yu X; Wang J; Hayes BC; Davies MA; Lizee G; Esmaeli B; Woodman SE
    Clin Cancer Res; 2012 Aug; 18(16):4345-55. PubMed ID: 22733540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells.
    Musi E; Ambrosini G; de Stanchina E; Schwartz GK
    Mol Cancer Ther; 2014 May; 13(5):1044-53. PubMed ID: 24563540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chloroquine Sensitizes
    Truong A; Yoo JH; Scherzer MT; Sanchez JMS; Dale KJ; Kinsey CG; Richards JR; Shin D; Ghazi PC; Onken MD; Blumer KJ; Odelberg SJ; McMahon M
    Clin Cancer Res; 2020 Dec; 26(23):6374-6386. PubMed ID: 32933997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype.
    Ho AL; Musi E; Ambrosini G; Nair JS; Deraje Vasudeva S; de Stanchina E; Schwartz GK
    PLoS One; 2012; 7(7):e40439. PubMed ID: 22808163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance.
    Ambrosini G; Pratilas CA; Qin LX; Tadi M; Surriga O; Carvajal RD; Schwartz GK
    Clin Cancer Res; 2012 Jul; 18(13):3552-61. PubMed ID: 22550165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional characterization of uveal melanoma oncogenes.
    Ma J; Weng L; Bastian BC; Chen X
    Oncogene; 2021 Jan; 40(4):806-820. PubMed ID: 33262460
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein kinase C inhibitors sensitize GNAQ mutant uveal melanoma cells to ionizing radiation.
    Cerne JZ; Hartig SM; Hamilton MP; Chew SA; Mitsiades N; Poulaki V; McGuire SE
    Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2130-9. PubMed ID: 24595385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma.
    Moore AR; Ran L; Guan Y; Sher JJ; Hitchman TD; Zhang JQ; Hwang C; Walzak EG; Shoushtari AN; Monette S; Murali R; Wiesner T; Griewank KG; Chi P; Chen Y
    Cell Rep; 2018 Feb; 22(9):2455-2468. PubMed ID: 29490280
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.
    Park JJ; Stewart A; Irvine M; Pedersen B; Ming Z; Carlino MS; Diefenbach RJ; Rizos H
    Cancer Gene Ther; 2022 Oct; 29(10):1384-1393. PubMed ID: 35352024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined PKC and MEK inhibition for treating metastatic uveal melanoma.
    Sagoo MS; Harbour JW; Stebbing J; Bowcock AM
    Oncogene; 2014 Sep; 33(39):4722-3. PubMed ID: 24413085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent and Yet Unreported GNAQ and GNA11 Mutations are Found in Uveal Melanomas.
    Schneider B; Riedel K; Zhivov A; Huehns M; Zettl H; Guthoff RF; Jünemann A; Erbersdobler A; Zimpfer A
    Pathol Oncol Res; 2019 Oct; 25(4):1319-1325. PubMed ID: 29209985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinome profiling identifies MARK3 and STK10 as potential therapeutic targets in uveal melanoma.
    Baqai U; Kurimchak AM; Trachtenberg IV; Purwin TJ; Haj JI; Han A; Luo K; Pachon NF; Jeon A; Chua V; Davies MA; Gutkind JS; Benovic JL; Duncan JS; Aplin AE
    J Biol Chem; 2023 Dec; 299(12):105418. PubMed ID: 37923138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Mutation Rates of GNAQ or GNA11 in Cases of Uveal Melanoma in Japan.
    Ominato J; Fukuchi T; Sato A; Yamaguchi N; Kobayashi K; Cho H; Oyama T; Ajioka Y
    Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):658-663. PubMed ID: 28248732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma.
    Arang N; Lubrano S; Ceribelli M; Rigiracciolo DC; Saddawi-Konefka R; Faraji F; Ramirez SI; Kim D; Tosto FA; Stevenson E; Zhou Y; Wang Z; Bogomolovas J; Molinolo AA; Swaney DL; Krogan NJ; Yang J; Coma S; Pachter JA; Aplin AE; Alessi DR; Thomas CJ; Gutkind JS
    Cell Rep Med; 2023 Nov; 4(11):101244. PubMed ID: 37858338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.